Ageing is biology. Can it become engineering?

One process, many points of failure

The hallmarks framework describes interacting features of ageing, from genomic instability and epigenetic alterations to loss of proteostasis, mitochondrial dysfunction, senescence and chronic inflammation. It organises questions; it does not establish that targeting any one feature will rejuvenate a person. [1]

These categories are an Ethernia reading map, not a replacement for the scientific framework. They help connect an intervention’s target to the outcome it is supposed to change. A stronger mechanism is useful—but only one part of the argument.

Every leap needs its own evidence

A molecule can change a pathway in a dish, improve a phenotype in a mouse and still fail to help a patient. Delivery, dose, biological context and competing harms all change between those settings. The crucial question is not whether something “works”, but what happened, to whom, compared with what.

Healthspan, average lifespan and maximum lifespan are different targets. Preventing disability matters even without a survival effect. Extending average survival does not show that a species’ upper limit has shifted. Ethernia names the endpoint instead of treating “anti-ageing” as a result.

Capacity remains part of the frontier

A future therapy has to work in an organism that moves, sleeps and responds to its environment. Physical capacity offers measurable endpoints; recovery and circadian behaviour are additional research questions. An observational sleep study linked regularity with mortality risk, but that association alone cannot establish that changing a sleep schedule prolongs life. [2]

Read the physical capacity dossier for the distinction between fitness associations and randomized functional outcomes.

The road to radical longevity

Could a person remain healthy for 150 years or longer? It is an ambitious research question, not an established outcome or a responsible forecast. A convincing route would require coordinated control of damage, cancer risk, tissue identity, immune function and delivery across the body. Solving one tissue problem is an important milestone without being whole-body rejuvenation.

Over five or ten years, useful progress might look like better measurements and narrowly targeted therapies. Twenty- and fifty-year scenarios are much more uncertain: discoveries, delivery barriers and unexpected harms could change the path. These are planning horizons, not predictions. No date on a roadmap can substitute for a controlled result.

Follow partial reprogramming, senescent-cell targeting and biological clocks to see where individual pieces stand.

Beyond a single intervention

Radical longevity would need more than a better supplement. These are questions for a future research programme, not claims of demonstrated treatments.

Our first detailed entry into this frontier is partial cellular reprogramming. Additional technology dossiers will be added when their evidence can be examined at the same depth.